title: Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction.
abstract: BACKGROUND
  Ventricular remodeling after acute myocardial infarction (AMI) is associated with increased morbidity and mortality. ELITE II study showed that losartan, an angiotensin receptor blocker, shows a survival benefit to the same degree as captopril, an angiotensin-converting enzyme inhibitor, does in patients with heart failure. However, recent OPTIMAAL study showed that clinical outcomes after losartan are not superior to those after captopril in patients with AMI. We examined the effect of losartan on ventricular remodeling after AMI comparatively with that of enalapril.
  
  
  METHODS
  We enrolled 203 consecutive patients with AMI (mean age 62 +/- 11 years). All patients underwent primary percutaneous coronary intervention and were randomly assigned to losartan (25-50 mg, n = 101) or enalapril (2.5-10 mg, n = 102) treatment. Biplane left ventriculography was performed just after primary percutaneous transluminal coronary angioplasty (acute phase) and 6 months after the onset of AMI.
  
  
  RESULTS
  Any of the maximal creatine kinase level, left ventricular end-diastolic volume index, end-systolic volume index, and ejection fraction measured at acute phase was not different between losartan and enalapril groups. However, changes in left ventricular end-diastolic index (18 +/- 25 vs 8 +/- 24 mL/m2) and left ventricular end-systolic volume index (10 +/- 20 vs 2 +/- 18 mL/m2) from acute phase to 6 months were significantly greater in losartan than in enalapril group. Change in left ventricular ejection fraction (0.2% +/- 10.3% vs 3.4% +/- 11.6%) from acute phase to 6 months was significantly smaller in losartan than in enalapril group. The plasma level of brain natriuretic peptide at 6 months was significantly higher in losartan than in enalapril group (all P < .05).
  
  
  CONCLUSIONS
  These indicate that enalapril suppresses ventricular remodeling after AMI more effectively than losartan.
authors.affiliation: Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Onodera
authors.forename: Toshiro
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Yujin
authors.initials: Y
authors.lastname: Tamura
authors.forename: Naotaka
authors.initials: N
authors.lastname: Maeda
authors.forename: Takumi
authors.initials: T
authors.lastname: Higuma
authors.forename: Shingo
authors.initials: S
authors.lastname: Sasaki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Mori
authors.forename: Fuminobu
authors.initials: F
authors.lastname: Yoshimachi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishizaka
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hanada
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Osanai
authors.forename: Ken
authors.initials: K
authors.lastname: Okumura
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D004656:Enalapril / Q000494:pharmacology*; D005260:Female; D006801:Humans; D019808:Losartan / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D016277:Ventricular Function, Left; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D019808:Losartan